Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02611167 · ClinicalTrials.gov registry record · Phase 1
Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Idiopathic Parkinson's Disease
A Phase 1 study, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT02611167 is a Phase 1 study that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 20 participants.
The verdict
NCT02611167, a Phase 1 study, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety, feasibility, and efficacy of intravenous allogeneic bone marrow-derived mesenchymal stem cell (MSC) therapy for idiopathic Parkinson's disease (iPD).
Interventions
- BIOLOGICAL Allogeneic bone marrow-derived MSCs (1 x 10 6 MSC/kg)
- BIOLOGICAL Allogeneic bone marrow-derived MSCs (3 x 10 6 MSC/kg)
- BIOLOGICAL Allogeneic bone marrow-derived MSCs (6 x 10 6 MSC/kg)
- BIOLOGICAL Allogeneic bone marrow-derived MSCs (10 x 10 6 MSC/kg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-11-01 |
| Est. Completion | 2019-09-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02611167
The ClinicalTrials.gov registry entry for NCT02611167 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Allogeneic bone marrow-derived MSCs (1 x 10 6 MSC/kg) is the first listed.
NCT02611167 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02611167 about?
NCT02611167 is a clinical study titled "Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Idiopathic Parkinson's Disease". The purpose of this study is to assess the safety, feasibility, and efficacy of intravenous allogeneic bone marrow-derived mesenchymal stem cell (MSC) therapy for idiopathic Parkinson's disease (iPD).
What is the current status of trial NCT02611167?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2017-11-01. Estimated completion is 2019-09-18.
What interventions are being tested in trial NCT02611167?
The interventions under investigation include: Allogeneic bone marrow-derived MSCs (1 x 10 6 MSC/kg) (BIOLOGICAL), Allogeneic bone marrow-derived MSCs (3 x 10 6 MSC/kg) (BIOLOGICAL), Allogeneic bone marrow-derived MSCs (6 x 10 6 MSC/kg) (BIOLOGICAL), Allogeneic bone marrow-derived MSCs (10 x 10 6 MSC/kg) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02611167?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.